Mutations of the human B-RAF gene are detected in f8% of cancer samples, primarily in cutaneous melanomas (70%). The most common mutation (90%) is a valine-to-glutamic acid mutation at residue 600 (V600E; formerly V599E according to previous nomenclature). Using a Cre/Lox approach, we have generated a conditional knock-in allele of V600E B-raf in mice. We show that widespread expression of V600E B-Raf cannot be tolerated in embryonic development, with embryos dying f7.5 dpc. Directed expression of mutant V600E B-Raf to somatic tissues using the IFN-inducible Mx1-Cre mouse strain induces a proliferative disorder and bone marrow failure with evidence of nonlymphoid neoplasia of the histiocytic type leading to death within 4 weeks of age. However, expression of mutant B-Raf does not alter the proliferation profile of all somatic tissues. In primary mouse embryonic fibroblasts, expression of endogenous V600E B-Raf induces morphologic transformation, increased cell proliferation, and loss of contact inhibition. Thus, V600E
Introduction
Raf oncogenes were first identified as transforming genes in retroviruses that caused tumors in mice and chickens (1, 2) . Oncogenic homologues of C-Raf and B-Raf were associated with the induction of carcinomas, sarcomas, and cancers of the hemopoietic lineage in these species (3, 4) . It has since been discovered that oncogenic mutations of the B-RAF gene are present in human cancer samples (5) . This study analyzed >900 cancer samples and human cancer cell lines and detected the presence of B-RAF missense mutations in f70% of human malignant melanomas. B-RAF mutations are also present at a high frequency in papillary thyroid cancer (36-53%; refs. 6-8) , colorectal cancer (5-22%; ref. 9) , and serous ovarian cancer (30%; ref. 10 ) and at a low frequency in a wide variety of other cancers (1-3%; refs. 5, 11, 12) .
Thus, in a similar way to RAS oncogenes that are detected in 15% to 30% of human cancers (13) , B-RAF mutations are a critical event in the development of many human neoplasias.
Over 30 missense B-RAF mutations have now been identified in cancer samples (11, 14) . The most common mutation, accounting for f90% of all those detected, is T1799A resulting in a glutamic acid-to-valine substitution at position 600 within the activation segment of the B-Raf kinase domain.
V600E B-Raf induces 500-fold more active basal B-Raf kinase activity than basal WT B-RAF and exceeds G12V RAS-induced WT B-RAF activity (14) . Recent structural studies have shown that this is due to the ability of the V600E mutation to disrupt the normal hydrophobic interaction between the activation segment and P-loop that maintains basal B-Raf in an inactive conformation (14) . In WT B-RAF, phosphorylation of residues Thr 599 and Ser 602 normally disrupt this interaction, allowing activation of B-RAF. The increased activity of V600E B-RAF has the effect of stimulating endogenous, basal mitogen-activated protein/extracellular signal-regulated kinase (MAP/ERK) kinase (MEK) and ERK1/2 activation, leading to increased cell proliferation and survival (14) (15) (16) (17) . The effect of V600E B-RAF on proliferation in mouse melanocytes and melanomas can be reversed by treatment of these cells with MEK inhibitors or with small interfering RNA (siRNA) to B-RAF. Thus, this mutant is thought to transform and mediate its tumorigenic effects in a similar way to oncogenic RAS. This is reinforced by the fact that B-RAF and RAS mutations are rarely present in the same cancer samples, indicating that they may have overlapping functions in tumorigenesis (5, 11, 12) . Although V600E B-RAF has the ability to induce G 0 -G 1 -S progression in tissue culture systems, it is not clear whether this is the case in tumor development in vivo. Oncogenic B-RAF mutations have been detected in benign nevi and premalignant colon polyps, suggesting that additional mutations in other key oncogenes/ tumor suppressor genes are required to unleash the tumorigenic effects of B-RAF (9, 18) . Candidate genes for such additional mutation are INK4A and PTEN that are frequently found mutated in melanomas (19, 20) . Work in tissue culture systems has also shown that the ability of the RAF/MEK/ERK cascade to induce G 0 -G 1 -S cell cycle progression is dependent on the cooperative activation of the phosphatidylinositol 3-kinase (PI3K)/PDK1/AKT pathway (21) or inactivation of cyclin-dependent kinase inhibitors (22, 23) , including p16
INK4a (24, 25) . To investigate how B-RAF is involved in tumorigenesis, and whether oncogene/tumor suppressor gene cooperation has a key function in development of tumors with B-RAF mutations, we have produced a tractable mouse model that mimics the somatic expression of V600E B-Raf in human cancers. These transgenic mice contain a heterozygous knock-in mutation of V600E B-raf whose expression is determined by the presence or absence of a Lox-STOP-Lox (LSL) cassette. We show that following deletion of LSL by the Cre recombinase, expression of V600E B-Raf in somatic tissues leads to development of some hallmarks of cancer in mice.
Materials and Methods
Generation of LSL-B-raf V600E mice. The LSL targeting vector was assembled by cloning left, middle, and right arms in the ploxP-neo-loxP vector. The right arm fragment contains exon 15 with the T1799A mutation. The middle arm contains a LSL cassette with a cDNA encoding exons 15 to 18 of mouse B-raf. This was PCR amplified from a mouse B-raf cDNA clone. The forward primer for this PCR reaction had the sequence 5V -TACT-AACCATGCCTTCTTCTTTTTCCTACAGATATATTTCTTCATGAAGACCT-CACGGT-3Vand contained 31 nucleotides corresponding to a splice acceptor sequence from the a-globin gene followed by 28 nucleotides corresponding to exon 15 of the mouse B-raf gene. The reverse primer had the sequence 5V -CGAGTGAGAGACACAAAAAATTCCAACACACTATTGTTGCTACCT-TACTTTATTGTCTCACTC-3Vand contained 35 nucleotides corresponding to the a-globin pause site and 28 nucleotides corresponding to the 3V -untranslated region of the mouse B-raf gene. The vector was electroporated into E14.1 embryonic stem cells, and homologous recombination events were identified. Positive embryonic stem clones were injected into mouse C57BL6 blastocysts and chimeric mice derived using standard procedures. Inheritance of the targeted allele was assessed by PCR genotyping (26, 27) of mouse tail DNA using primers A (5V -GCCCAGGCTCTTTATGAGAA-3V ) and B (5V -GCTTGGCTGGACGTAAACTC-3V ) for the LSL-B-raf V600E -targeted allele combined with primers A and C (5V -AGTCAATCATCCACAGAGACCT-3V ) for the wild-type allele (Fig. 1) . A breeding colony of LSL-B-raf V600E mice were established by backcrossing on the C57BL6 background. Genotyping of offspring from LSL-B-raf V600E Â Cre crosses was done by using a multiplex PCR reaction using primers A to C as well as primers D (5V -GTTCGCAA-GAACCTGATGGACA-3V ) and E (5V -CTAGAGCCTGTTTTGCACGTTC-3V ) for identifying the Cre gene. To detect the Lox-B-raf V600E allele, primers A and C were used. All PCRs were done using Reddymix PCR reagent (ABgene, Surrey, United Kingdom) with 35 cycles of 94jC for 30 seconds, 60jC for 30 seconds, and 72jC for 30 seconds.
Histology, immunohistochemistry, and proliferation assays. Mouse tissues were processed for histology by previously described methods (26) . Sections were either stained with H&E or used for immunohistochemistry with antibodies for Ki67 (Novocastra Laboratories Ltd., Newcastle upon Tyne, United Kingdom), Mac-2 (Cedarlane Laboratories Ltd., Hornby, Ontario, Canada), and phospho-ERK (Cell Signaling Technology, Beverly, MA) or used for terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) analysis as described previously (26, 27) . To assess proliferation, mice were injected with 10 Ag/mL bromodeoxyuridine (BrdUrd), and tissues were either analyzed by immunohistochemistry with an a-BrdUrd antibody or, in the case of the spleen, cells were dissociated by passing through a mesh, counted, and then stained with a-BrdUrd-FITC and analyzed by fluorescence-activated cell sorting (FACS) using the kit and method provided by BD Biosciences (San Jose, CA). Bone marrow was collected from the femurs of freshly culled mice, and cells were quantitated using a Coulter counter (Becton Dickinson, Mountain View, CA).
Northern blot analysis. Mouse spleens were snap-frozen in liquid nitrogen and ground to a powder. Total cellular RNA was isolated using the RNAzol-B technique (Biogenesis Ltd., Poole, United Kingdom). RNA was resolved by denaturing 1.2% agarose/18% (v/v) formaldehyde gel electrophoresis and transferred to GeneScreen (Dupont, Boston, MA), before UV cross-linking. cDNA inserts were labeled (Random primers DNA labeling system, Amersham Biosciences, Buckinghamshire, United Kingdom) using [a- 32 P]dATP (Amersham; 3,000 Ci/mmol). Filters were hybridized in a solution containing 7% (w/v) SDS, 1% (w/v) bovine serum albumin, 0.25 mol/L NaCl, and 0.5 mol/L Na 2 HPO 4 buffer (pH 7.2) at 65jC for 16 hours. They were washed sequentially at 65jC in 4Â SSC, 0.5Â SSC, and 0.2Â SSC, each containing 0.1% SDS, and resolved by autoradiography.
Western blots and kinase assays. Mouse tissues were snap-frozen in liquid nitrogen and homogenized in NP40 lysis buffer [50 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 0.5% NP40, 5 mmol/L NaF] with 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L aprotinin, 1 mmol/L leupeptin, and 1 mmol/L sodium orthovanadate. Western blots were carried out as described previously (28) . B-Raf kinase assays were done using the immunoprecipitation kinase cascade assay as previously reported (29) Mouse embryonic fibroblast analysis. Mouse embryonic fibroblasts (MEF) were isolated and cultured from homogenized E14.5 embryos arising from timed matings between LSL-B-raf V600E animals and wild-type C57BL6 animals using standard methods (26) . MEFs were transfected with the pCrePac plasmid using a Nucleofector under the MEF conditions recommended by the manufacturer (Amaxa Biosystems, Koln, Germany). Forty-eight hours following transfection, cells were photographed and processed for immunofluorescence analysis of the actin cytoskeleton by staining with FITC-phalloidin as described previously (30) . For proliferation, mock-transfected and Cre-transfected cells, 24 hours after transfection, were placed in serum-free media for 20 hours and then either left unstimulated or stimulated with 10% (v/v) FCS for 16 hours. BrdUrd incorporation assays were done by using the BrdUrd labeling and detection kit (Roche, Indianapolis, IN). The percentage of BrdUrd-positive cells was visualized by fluorescence microscopy using a Zeiss Axiophot microscope. For protein analysis, 24 hours following transfection, cells were serum starved for 20 hours and then stimulated with FCS for 10 minutes or for 16 hours. Protein lysates were generated, and Western blots were carried out as described above. Focus-forming assays were done as described elsewhere (31) , and agar assays were done as described previously (32) .
Results
Numbering of the amino acids in B-Raf. The valine residue that is most commonly mutated in human cancer was originally reported as being at position 599 of the human B-Raf protein. However, as highlighted by Wellbrock et al. (33) , more recent sequencing data have shown that there was a previous error in the sequencing of the B-RAF 5Vcoding region, such that this valine is now reclassified as being at residue 600. In the mouse, the 5Vcoding region has not yet been fully sequenced and thus the residue number of the equivalent valine is not known. For the present purposes, this residue will also be referred to as Val 600 . Generation of LSL-B-raf V600E mice. We used the Cre-LoxP system to generate transgenic animals containing a conditional knock-in allele that expresses V600E B-Raf only after Cre-mediated recombination (Fig. 1A) . The targeting vector contained a left arm spanning exon 14 and a right arm containing exon 15 with the B-raf V600E mutation, representing a T1799A nucleotide change. These two arms were separated from each other by the neo R gene and a minigene cDNA encoding wild-type exons 15 to 18. Three LoxP sequences were present in the vector and two polyadenylation STOP sequences. In this arrangement, wild-type B-Raf is expressed from the targeted gene with exons 15 to 18 being encoded by the minigene. Introduction of the Cre recombinase allows deletion of the LSL cassette and expression of V600E B-Raf. The vector was introduced into embryonic stem cells, and homologous recombination events were identified. Mice were generated from the positive clones, and a breeding colony was established on the C57BL6 background. PCR genotyping confirmed the inheritance of the LSL-B-raf V600E allele (Fig. 1B) . Expression of V600E B-Raf in embryogenesis. We generated mice that permanently express V599EBRaf in all tissues. This was achieved by crossing the LSL-B-raf V600E mice to heterozygous CMV-Cre mice that express the Cre transgene in germ cells as well as in a mosaic manner during development (34) . Multiplex PCR genotyping was used to identify LSL-B-raf V600E + CMV-Cre animals (Fig. 1B) . These were then analyzed by PCR for the presence of the Cre-deleted Lox-B-raf V600E allele expressing V600E B-Raf (Fig. 1C) . Genotyping of the surviving offspring revealed no viable LSL-B-raf V600E + CMV-Cre animals ( Table 1 ). The LSL-B-raf V600E and CMV-Cre mice were thus mated at timed intervals, and embryos were harvested at various ages of gestation. LSL-B-raf V600E + CMV-Cre embryos were obtained at the expected frequency at E7.5, but lethality was observed from this point onwards. At E7.5, all embryos with the Lox-B-raf V600E allele were abnormal and in the process of being reabsorbed (Fig. 1D) . Only those embryos that were mosaic for the Lox-B-raf V600E and LSL-B-raf V600E alleles survived to later ages of gestation (Table 1) , but even these all died before birth. This indicates that the expression of V600E B-Raf in gestation is lethal to the animal, although the embryos are able to implant.
Somatic expression of V600E B-Raf. To examine the effect of the oncogenic V600E B-raf mutation on somatic tissues, we crossed the NOTE: Analysis of embryos at E7.5 and E8.5 showed that LSL-B-raf V600E + CMV-Cre embryos were obtained at the expected frequency at these developmental ages but were obtained at reduced frequencies at later developmental ages, and none survived to birth. At E7.5 and E8.5, all LSL-Braf V600E + CMV-Cre embryos containing the Lox-B-raf V600E allele were abnormal and in the process of being reabsorbed (see Fig. 1D ). *These later surviving embryos were all mosaic for the LSL-B-raf V600E and Lox-B-raf V600E alleles. Fig. 2A; refs. 36, 37 ). This is likely because of endogenous IFN production in response to a subclinical infection or other stimulus. All of the LSL-B-raf V600E + Mx1-Cre animals died before 4 weeks of age, whereas the LSL-B-raf V600E À Mx1-Cre animals survived the normal life span of a mouse with no symptoms (Fig. 2A) . Wild-type mice with the Mx1-Cre allele also showed no phenotype (data not shown). PCR analysis of DNA from various tissues of LSL-B-raf V600E + Mx1-Cre animals indicated the presence of the Lox-B-raf V600E allele in many tissues, including the spleen, liver, lung, and heart (Fig. 2B) . However, this allele was present at considerably lower levels in some tissues, particularly, the kidney, testis, gut, and thymus.
Tissues with the Lox-B-raf V600E allele were subjected to further investigation. No alterations were detected in the morphology or pathology of the lung, heart, kidney, gut, or testis (data not shown). However, the spleen and liver were abnormal. Splenomegaly was observed in all LSL-B-raf V600E + Mx1-Cre animals (Fig. 2C ). 2C). Histologic analysis of spleen sections showed the infiltration of a proliferating, pleomorphic population of cells with abundant eosinophilic cytoplasm and irregular nuclei as well as extramedullary sites of hemopoiesis (Fig. 2D) . The spleens of the LSL-B-raf V600E + Mx1-Cre mice also stained far more strongly with antibodies for the S-phase marker Ki67 as well as phospho-ERK than LSL-B-raf V600E À Mx1-Cre spleens, but there were no noticeable changes in apoptosis, as measured by TUNEL analysis (Fig. 2D) . To quantitate proliferation in vivo, mice were injected with BrdUrd, and incorporation into splenocytes was measured by FACS analysis (Fig. 2E) . The splenocytes of LSL-B-raf V600E + Mx1-Cre Cre mice (mean = 51.1%, n = 6) proliferated 2-3Â more than splenocytes from LSL-B-raf V600E À Mx1-Cre mice (mean = 22.6%, n = 6, P = 0.0015). To identify which cell types were amplifying in the spleen, Northern blot analysis was done on spleen RNA with probes for genes expressed in the myeloid (myeloperoxidase and lysozyme M), lymphoid (CD19, rag-1, and VpreB1), stem cell (Sca1), and erythroid (erythropoietin receptor) lineages. No consistent increase in expression of any of these genes was observed in LSL-B-raf V600E + Mx1-Cre spleens compared with LSL-B-raf V600E À Mx1-Cre spleens (Fig. 2F) . However, the spleens from LSL-Braf V600E + Mx1-Cre mice stained strongly for Mac2 (Fig. 2G ), indicating the presence of an amplified population of histiocytes.
Histologic analysis of the liver also indicated the presence of extramedullary sites of hemopoiesis. Ki67 staining indicated increased proliferation in the liver of LSL-B-raf V600E + Mx1-Cre Figure 2 . Analysis of mice resulting from Lox-B-raf V600E Â Mx1-Cre intercrosses. A, % survival of LSL-B-raf V600E + Mx1-Cre animals versus LSL-B-raf V600E À Mx1-Cre animals at various ages after birth. B, PCR genotyping to detect Lox-B-raf V600E allele in DNA from various tissues derived from LSL-B-raf V600E + Mx1-Cre mice. C, splenomegaly in LSL-B-raf V600E + Mx1-Cre mice. Left, increase in size of the spleen of P21 animals. Right, pooled weight data from four spleens of LSL-B-raf V600E F Mx1-Cre mice at P21. LSL-B-raf V600E + Mx1-Cre mice have a mean spleen weight of 0.2 g compared with 0.04 g for the control LSL-B-raf V600E À Mx1-Cre mice. Columns, means; bars, SD. D, histologic analysis of spleen sections from LSL-B-raf V600E F Mx1-Cre mice. Spleen sections were either stained with H&E, with antibodies for Ki67 or phospho-ERK, or processed for TUNEL analysis. Bar, 50 Am (the same for all sections). E, proliferation analysis of spleens from LSL-B-raf V600E F Mx1-Cre mice. Mice were injected with BrdUrd, splenocytes were isolated, and the % incorporation of BrdUrd was assessed by FACS analysis. Columns, means; bars, SD. F, Northern blot analysis of spleen RNA isolated from LSL-B-raf V600E F Mx1-Cre mice. Northern blots were probed with the markers indicated. G, histologic analysis of spleen sections from LSL-B-raf V600E F Mx1-Cre mice with a histiocyte marker. Spleen sections were stained with a Mac-2 antibody to detect histiocyte amplification. Bar, 50 Am. mice, associated with increased phospho-ERK staining (Fig. 3A) . However, in addition to this, the liver of these mice was also in the process of undergoing apoptosis as indicated by increased TUNEL staining (Fig. 3A) . The Lox-Braf V600E allele was strongly detected in the bone marrow of LSL-B-raf V600E + Mx1-Cre animals. This was associated with the virtual absence of RBC in the bone marrow and a reduction in the production of WBC by at least 50% (Fig. 3B) . Circulating RBC and WBC were also significantly reduced (data not shown). Additionally, LSL-B-raf V600E + Mx1-Cre animals developed Lox-B-raf V600E -containing histiocytes (Fig. 2B) at extranodal sites that were predominantly observed on the skin (Fig. 3C) , although occasionally on the gut wall. These were detectable at birth and contained proliferating, phospho-ERK positive cells with a typical histiocyte morphology that stained strongly for Mac2 (Fig. 3D) . The appearance of splenomegaly and Mac2-positive staining cells in the spleen and at extranodal sites is consistent with a diagnosis of nonlymphoid leukemia of the histiocytic type (according to Bethesda classification of hemopoietic neoplasms. 4 Expression of V600E B-Raf induces activation of the B-RAF/ mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase cascade. We did B-Raf kinase assays on protein lysates generated from spleen, liver, and lung of LSL-B-raf V600E F Mx1-Cre animals. B-Raf kinase activity was elevated by f11-fold in the spleen and by f3-fold in the liver and lung of LSL-B-raf V600E + Mx1-Cre animals compared with controls (Fig. 4A) . Western blot analysis also showed that levels of phospho-MEK and phospho-ERK were significantly increased in tissues affected by the expression of V600E B-Raf (i.e., the spleen and liver). With regard to cyclin D1, levels of expression were increased in the spleen of LSL-B-raf V600E + Mx1-Cre mice but not the liver, probably because this tissue is also undergoing apoptosis (Fig. 3A) . However, tissues that were not morphologically affected by the mutation (lung or thymus) showed an increase in levels of phospho-MEK but not an increase in phospho-ERK or cyclin D1 levels (Fig. 4B) .
Expression of V600E B-Raf induces transformation of primary mouse embryonic fibroblasts. To further investigate the transforming effects of endogenous V600E B-Raf, we derived primary MEFs from LSL-B-raf V600E mice and transfected these cells with a plasmid expressing the Cre recombinase. LSL-B-raf V600E MEFs without Cre showed a typical nontransformed morphology (Fig. 5A) . However, transfection with the Cre plasmid induced morphologic transformation and collapse of the actin cytoskeleton (Fig. 5A) . In addition, LSL-B-raf V600E MEFs with the Cre plasmid showed a significant increase in proliferation (Fig. 5B) . When serum starved, 6.75% of mock-transfected cells entered S phase, whereas in the presence of Cre 9.57% of cells entered S phase (P < 0.002). In the presence of FCS, 11.5% of cells without Cre entered S phase, whereas in the presence of Cre, 26.2% of cells entered S phase (P < 10 -6 ). Thus, serum-starved, Cre-containing LSL-B-raf V600E MEFs undergo proliferation at a similar rate to serum-stimulated, mock-transfected LSL-B-raf V600E MEFs, although proliferation of the Cre-containing LSL-B-raf
V600E
MEFs was further stimulated by the presence of growth factors. Concomitant with the increase in proliferation in serum-starved, Cre-containing cells, levels of phospho-ERK (Fig. 5C ) and cyclin D1 (Fig. 5D) were increased in these cells compared with nontransfected controls, but p21 CIP1 levels were drastically reduced Figure 3 . Analysis of tissues from mice resulting from LSL-B-raf V600E Â Mx1-Cre intercrosses. A, histologic analysis of liver sections from LSL-B-raf V600E F Mx1-Cre mice. Liver sections were either stained with H&E, with a Ki67 antibody, with a phospho-ERK antibody or processed for TUNEL analysis. Right, H&E section was photographed at higher magnification (Â400) to indicate site of hemopoiesis (black arrow ) in the mutant liver. Bar, 50 Am (the same for all sections) except for 25 Am (enlarged H&E section, right ) . B, analysis of bone marrow from LSL-B-raf V600E F Mx1-Cre mice. Bone marrow cells were isolated from the femurs of LSL-B-raf V600E F Mx1-Cre mice and analyzed by the Coulter counter. There are far fewer RBC and WBC in the bone marrow of LSL-B-raf V600E + Mx1-Cre mice (shaded area ) than LSL-B-raf V600E À Mx1-Cre mice (clear area). PCR analysis of DNA from bone marrow of LSL-B-raf V600E + Mx1-Cre animal, indicating the presence of the Lox-B-raf V600E allele. C, photograph of histiocyte arising on skin of LSL-B-raf V600E + Mx1-Cre animal. D, histologic analysis of histiocyte sections from LSL-B-raf V600E F Mx1-Cre mice. Sections were either stained with H&E, with antibodies for Ki67, phospho-ERK, or Mac-2, or processed for TUNEL analysis. Bar, 50 Am. 4 http://emice.nci.nih.gov. (Fig. 5D ) . LSL-B-raf V600E primary MEFs transfected with the Cre plasmid also acquired the ability to grow to a very high density, with loss of contact inhibition and focus formation after 3 weeks in culture (Fig. 5E ), and were able to form very small colonies when grown in soft agar (Fig. 5F ).
Discussion
We report the generation of mice with a LSL conditional knockin mutation of V600E Braf, whereby the expression of endogenous V600E B-Raf is dependent on delivery of the Cre recombinase and deletion of the LSL cassette. We show that somatic tissues expressing endogenous V600E B-Raf have elevated B-Raf kinase activity, elevated levels of phospho-MEK, phospho-ERK, and cyclin D1 expression, and increased proliferation. In addition, expression of V600E B-Raf in primary MEFs induces morphologic transformation as well as hyperproliferation, the loss of contact inhibition, and a weak ability to grow in an anchorage-independent manner. These results show that at least in some primary mouse cells, V600E B-Raf is able to induce several hallmarks of transformation without evidence for the involvement of a second cooperating oncogene or loss of a key tumor suppressor gene.
Classic studies have previously established a requirement for oncogene cooperation in transformation of primary cells (38) . RAS and RAF oncogenes overexpressed in primary cells have been shown to induce cell senescence unless accompanied by mutations in the p19 ARF /p53 pathway (23) (24) (25) . However, it has recently been shown that the expression of lower, physiologic levels of G12D K-ras in mice promotes proliferation and partial transformation in primary cells, without a cooperating event (39) . These authors were able to indicate clear differences in the biological effects of overexpressed oncogenic K-ras, which induces senescence, versus oncogenic expression of endogenous K-ras at physiologic levels that induces proliferation. We have found that like G12D K-Ras, V600E B-Raf expressed at physiologic levels in mice can promote proliferation and partial transformation of some primary cell types. This is perhaps a more surprising result than that with oncogenic RAS as RAS has multiple effector pathways, notably, the RAF/ MEK/ERK and PI3K/PDK1/PKB pathways, both of which can impinge on the cell cycle, whereas oncogenic RAF is only known to activate the MEK/ERK pathway. However, our observations are consistent with previous data showing that the effects of V600E B-Raf on proliferation of mouse melanocytes and human melanoma cells containing the V600E B-Raf mutation can be reversed by siRNA to B-RAF (15) (16) (17) 40) . In the development of human malignant cancers in vivo, the situation may well be more complex as V600E B-Raf mutations are detected in a high proportion of benign melanocytic lesions (nevi) and premalignant colon polyps in which the cells are thought to be senescent (9, 18, 41, 42) . This has been taken as evidence that B-RAF activation itself is not sufficient to induce all hallmarks of cancer in vivo, at least in melanocytes and colonic epithelial cells.
We expressed V600E B-Raf ubiquitously, by crossing the LSL-B-raf V600E mice to CMV-Cre mice, and show that this cannot be tolerated in embryonic development with embryos harboring the Lox-B-raf V600E allele embryos dying before E7.5. This result is similar to that obtained with the ubiquitous expression of endogenous G12D K-ras, which also induces early embryonic lethality (39) . Using the Mx1-Cre strain, we found that the expression of V600E B-Raf in adult somatic tissues induces hyperproliferation as well as bone marrow failure. The effects on proliferation are highly tissue dependent. Pathologic effects on proliferation were observed in the Lox-B-raf V600E -containing spleen and liver, and the histiocytes were observed on the skin but not in the Lox-B-raf V600E -containing lung, kidney, or thymus, which showed no evidence for the presence of histiocytes. Despite this, similar levels of B-Raf kinase activity were observed in the Lox-B-raf V600E -containing lungs of LSL-B-raf V600E + Mx1-Cre mice compared with the Lox-B-raf V600E -containing livers. This observation may be related to the fact that there is no noticeable increase in levels of phospho-ERK in the lung of LSL-B-raf V600E + Mx1-Cre animals, although phospho-MEK levels are increased, which would suggest an uncoupling between B-RAF/MEK and ERK in the lung, possibly due to the action of tissue-specific MAP kinase phosphatases. The liver is affected in a complex way by the expression of V600E B-Raf. Higher levels of apoptosis are observed as well as increased proliferation. The increase in apoptosis may be an indirect consequence of the bone marrow failure and reduction in circulating RBC rather than a direct consequence of V600E B-Raf expression in this tissue.
Expression of V600E B-Raf using the Mx1-Cre strain leads to the development of a form of hemopoietic dysplasia with some of the characteristics of nonlymphoid leukemia of the histiocyte type, in which there is an amplification of circulating cells of the histiocyte/ macrophage lineage. At present, it is not clear why these cells in particular are susceptible to the proliferative effects of V600E B-Raf. Histiocytes have been observed in other mouse tumor models for cancer, particularly those on the C57BL6 strain background, including Bax/ARF double null mice (43) as well as mice expressing endogenous G12V K-ras (44). However, histiocytes are rare in humans and have not thus far been associated with the presence of B-RAF mutations. Indeed, despite the high level of expression of B-Raf in hemopoietic cells, B-RAF mutations are extremely rare in hemopoietic neoplasms, and none of those reported thus far represent V600E B-RAF mutations (45) (46) (47) . By contrast, NRAS and KRAS mutations occur in f30% of acute myeloid leukemias and myeloproliferative disorders (13) , and somatic activation of G12D K-ras in mice using the Mx1-Cre strain induces a similar myeloproliferative disorder (37, 48) , indicating that oncogenic B-RAF and RAS target different populations of Mx1-Cre-expressing cells.
Studies with Ras oncomice have clearly illustrated the importance of expression level in mediating the effects of oncogenic Ras on tumor development (39) . We have developed a tractable strain of transgenic mouse that allows the somatic expression of V600E B-Raf at physiological levels. The next important step is to deliver the Cre recombinase to these mice in such a way that it allows the somatic expression of V600E B-Raf in cell types most affected by B-RAF mutations in the development of human tumors, most notably melanocytes, papillary thyrocytes, and colonic and ovarian epithelial cells, as well as cancer stem cells. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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